EULAR Press Releases
News of November 2024
01. November 2024
Press Registration Now Open for the EULAR 2025 Congress in Barcelona
A landmark event in advancing rheumatology research and innovation.
—
The European Alliance of Associations for Rheumatology (EULAR) is thrilled to announce that press registration is now open for the EULAR 2025 Congress, set to take place from 11-14 June in vibrant Barcelona, Spain.
News of October 2024
29. October 2024
Unifying sJIA and Still's Disease
New Recommendations
—
EULAR – The European Alliance of Associations for Rheumatology – in partnership with the Paediatric Rheumatology European Society (PReS) has developed new recommendations for the diagnosis and management of Still’s disease, comprising the two diseases formerly known as systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
17. October 2024
EULAR Launches New Open-access Journal - EULAR Rheumatology Open (ERO)
Advancing Global Rheumatology Research with an Inclusive, Accessible Approach
—
The European Alliance of Associations for Rheumatology (EULAR) proudly announces the launch of its new open-access journal, a pioneering platform dedicated to advancing research and knowledge in the field of rheumatology. This innovative, online-only journal will be hosted by the globally renowned publisher Elsevier, providing researchers, healthcare professionals, and the wider scientific community with unrestricted access to the latest advancements in rheumatology.
14. October 2024
Modern Approach for Systemic Sclerosis
Updated recommendations
—
In 2017, EULAR – The European Alliance of Associations for Rheumatology – published recommendations on the treatment of systemic sclerosis (SSc). Since then, much new evidence – and new drugs – have become available, so the recommendations have been reviewed and updated. Several changes are significant.
News of August 2024
23. August 2024
European Alliance of Associations for Rheumatology and Elsevier Announce New Partnership
EULAR announces new partnership with Elsevier to publish Annals of the Rheumatic Diseases, beginning January 2025
—
23 August, 2024 - The European Alliance of Associations for Rheumatology (EULAR) announces a new partnership with Elsevier, a global leader in information and analytics, to publish its flagship scientific journal, Annals of the Rheumatic Diseases (ARD). The journal will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2025.
News of June 2024
17. June 2024
Advancing PRP Involvement in Rheumatology
Updated Recommendations
—
In 2011, EULAR – The European Alliance of Associations for Rheumatology – published the first set of recommendations focused on how best to involve patient representatives in scientific projects. This important work also defined the input of patient research partners (PRP), but their role has since evolved.
15. June 2024
Insights Into the Salivary Glands
New understanding of novel pathways in Sjögren's disease
—
Sjögren’s disease primarily affects the salivary and lacrimal glands, resulting in tissue inflammation characterised by the formation of tertiary lymphoid structures (TLS), and a loss of glandular function – resulting in dryness of the eyes and mouth, fatigue, and poor health-related quality of life. It is also known that salivary gland epithelial cells (SGEC) play a pathogenic role in Sjögren's disease. Two abstracts presented at the 2024 congress of EULAR – The European Alliance of Associations for Rheumatology – looked at Sjögren's disease, specifically around furthering our understanding of the role of the salivary glands.
15. June 2024
Holistic Approach to Care
The impact of lifestyle intervention in RA
—
EULAR – The European Alliance of Associations for Rheumatology – has previously made recommendations for lifestyle interventions in people with rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA).1 The overarching principles define the need for a healthy lifestyle, with specific recommendations that emphasise the importance of a healthy, balanced diet.1 Now, new work shared at the 2024 EULAR congress in Vienna is expanding on this, with data from a randomised controlled trial.
14. June 2024
Is Fish Intake Linked to JIA?
New data from a large, population-based prospective cohort
—
Juvenile idiopathic arthritis (JIA) results from a complex interplay of genetic and environmental factors. Past efforts to identify JIA’s environmental risk factors have been restricted due to limited high-quality data and small sample sizes, mirroring the rarity of the disease.
14. June 2024
Does BMO Induced by Mechanical Stress Progress to Structural Lesions?
Exploring MRI imaging findings in postpartum women
—
Immediately after childbirth, a large number of women have sacroiliac bone marrow oedema (BMO) visible on MRI. Although generally attributed to mechanical stress, these transient postpartum lesions bear a striking resemblance to the inflammatory lesions seen in axial spondyloarthritis (axSpA).
14. June 2024
Protection Against Disease and Treatment Toxicity
Investigating novel treatment options in systemic sclerosis
—
EULAR – The European Alliance of Associations for Rheumatology – updated its recommendations for systemic sclerosis (SSc) in 2023.1 Notably, four new therapies were added that had not been included in 2017 – highlighting how fast the field is changing. New, strong evidence is now available to help better manage patients with this life-threatening condition, but gaps remain.
14. June 2024
Are Patient Partners a Necessity in Research?
Honest feedback from the scientific community
—
EULAR – The European Alliance of Associations for Rheumatology – has long recognised the pivotal role of patients in the development of recommendations,1,2 and the role of patients in research is also evolving. But collaboration with patients in this way is relatively new, and trials or effectiveness studies are not yet available.2 Now, new survey data shared at the 2024 EULAR congress in Vienna shine a light on the views of the scientific community – specifically in the drive to find new outcomes and treatments for people with primary Sjögren’s disease.
14. June 2024
Encouraging Cooperation in Inflammatory Arthritis
Inspiration and dialogue on cross-sectoral management
—
There is a need to improve cross-sectoral care for people with inflammatory arthritis. The Danish Centre for Expertise in Rheumatology (CeViG) at the Danish Hospital for Rheumatic Diseases in Sønderborg, Denmark, is a unique institution – which aims to share knowledge with people involved in the care and management of inflammatory arthritis. EULAR – The European Alliance of Associations for Rheumatology – supports innovations in healthcare for arthritis. Now, new survey data presented at the 2024 EULAR congress showcase the benefits of cooperation between different stakeholders.
14. June 2024
Unpicking the Complexity of Systemic Sclerosis
New work exploring different facets of this heterogeneous disease
—
In 2023, EULAR – The European Alliance of Associations for Rheumatology – updated its recommendations for the treatment of systemic sclerosis (SSc), with many new inclusions around manifestations such as skin fibrosis and interstitial lung disease (ILD).1 However, there remains a need for better understanding of risk factors and more precise patient stratification based on organ-specific manifestations.
13. June 2024
EULAR Launches the EULAR Network of Trial Centres (ENTRI), a Unique Initiative Transforming the Way Clinical Trials Are Delivered
Stop searching, start researching! Your RMD clinical trials journey starts here
13. June 2024
Putting Rheumatic and Musculoskeletal Diseases (RMDs) at the Forefront of the Next European Union Healthcare Agenda
EULAR calls for a comprehensive European response to RMDs.
—
The European Alliance of Associations for Rheumatology (EULAR) is proud to announce the launch of its 2024 - 2029 European Manifesto, aimed at addressing the urgent need for a coordinated European response to Rheumatic and Musculoskeletal Diseases (RMDs), focusing particularly on the areas of quality of care, research, and social policy. This initiative comes at a critical juncture as Europe has elected new Members of the European Parliament (MEPs), highlighting the importance of prioritising health and socio-economic challenges, particularly those posed by RMDs.
13. June 2024
Survey Now Open: EULAR Invites Patients Across Europe to Participate in Groundbreaking Study on Rheumatic and Musculoskeletal Diseases
EULAR's new survey seeks to gather valuable insights from patients across Europe on the impact of rheumatic and musculoskeletal diseases (RMDs). Available online, the survey will soon be accessible in multiple European languages. Participation will help improve care and understanding of these conditions.
13. June 2024
Osteoarthritis: Associations and Comorbidities
Data from the multi-centre ComOA study
—
Osteoarthritis is the most common arthritis worldwide, and has an increasing global burden of disability and healthcare utilisation.1,2 It is also associated with various comorbidities, and this link has gained attention in recent years.
13. June 2024
Could Interferon Signature Aid in the Diagnosis and Stratification of Paediatric Sjögren’s?
Identifying potentially dysregulated molecular pathways
—
Due to differences in clinical presentation and limited knowledge, diagnosing Sjögren’s disease in children can be challenging. Although dysregulation of multiple immune response pathways has been shown in adults, few studies have investigated pathophysiological mechanisms in children. EULAR – The European Alliance of Associations for Rheumatology – held its 2024 congress in Vienna, where new work was unveiled on the potential value of the blood interferon signature in paediatric-onset Sjögren’s disease.
13. June 2024
Predictors for Organ Damage
Protecting children with SLE
—
Childhood-onset systemic lupus erythematosus (cSLE) is a chronic, severe autoimmune disorder that carries a risk of early organ damage.1 Identifying specific predictors in children is vital for preventing such damage. At their 2024 congress, EULAR – The European Alliance of Associations for Rheumatology – ran a session on paediatric rheumatology that showcased new work on the factors associated with damage accrual in cSLE, with a focus on corticosteroid regimens and maintenance of low disease activity.
13. June 2024
Tackling Issues in Childhood Arthritis
Raising awareness and highlighting transition issues
—
Rheumatological diseases can affect people during childhood, the most common being juvenile idiopathic arthritis (JIA). As well as a need to generally raise awareness of childhood arthritis, there is also a crucial need to ensure effective transition for these young patients from paediatric to adult care. EULAR – The European Alliance of Associations for Rheumatology – included sessions on childhood arthritis at its 2024 congress in Vienna.
13. June 2024
Reclarit: Self-management in Practice
New work to evaluate a digital health app in adult patients with RA
—
EULAR – The European Alliance of Associations for Rheumatology – recommends patient self-management for people with inflammatory arthritis.1,2 The intention is to empower people to acquire a good understanding of their disease and build their ability to deal effectively with the practical, physical, and psychological impacts.
13. June 2024
Unpicking the Pathogenesis of RA
New work on the precursors of inflammatory synovial macrophages
—
The exact origin and precursor differentiation route of tissue macrophages remains controversial. At the 2024 congress of EULAR – The European Alliance of Associations for Rheumatology – new work sheds light on blood precursors of pathogenic tissue macrophages.
13. June 2024
Low-dose Glucocorticoids in SLE
New evidence around use and thresholds in SLE
—
Glucocorticoids are a mainstay of treatment for systemic lupus erythematosus (SLE). But due to long-term adverse effects, dose reduction is becoming a crucial part of treat-to-target management goals. However, data regarding the optimum dose target are conflicting. Recommendations from EULAR – The European Alliance of Associations for Rheumatology – advise a glucocorticoid dose of no more than 5 mg/day.1 However, the threshold in the validated lupus low disease activity state (LLDAS) definition is no more than 7.5 mg/day.2 It is also still unclear whether it is safe and feasible to withdraw glucocorticoids after achieving remission.
13. June 2024
Achieving Drug-free Remission in axSpA
Exploring the role of tight control in early disease
—
Early therapeutic interventions in inflammatory rheumatic diseases have proven successful in inducing drug-free remission, and EULAR – The European Alliance of Associations for Rheumatology – recommends early intervention in arthritis,1 since conventional synthetic disease-modifying antirheumatic drugs (csDMARD) have been shown to slow disease progression in both rheumatoid and psoriatic arthritis.
13. June 2024
Implementing Physical Activity Recommendations
Identifying key barriers and facilitators
—
EULAR – The European Alliance of Associations for Rheumatology – has recommendations aimed at promoting health-enhancing physical activity,1 but despite the established benefits – and evidence supporting the efficacy of physical activity and exercise interventions in enhancing overall fitness, alleviating symptoms, improving quality of life, and positively impacting cardio-metabolic biomarkers – there are challenges, and a general gap between research findings and their implementation in real-world clinical settings.
12. June 2024
Testing the Systemic Score for Still’s Disease
New work presented at the 2024 EULAR congress
—
Still’s disease is an inflammatory disorder typically manifesting with fever, arthritis, and skin rash. It affects both children and adults, and has previously been known as systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Regardless of the name, people with Still’s disease are burdened by life-threatening complications.
12. June 2024
Predicting Response in Treatment-Naïve RA
Harnessing the power of multi-modal analysis
—
New work presented at the 2024 congress of EULAR – The European Alliance of Associations for Rheumatology – assesses the power of multi-modal analysis of synovial tissue inflammation in treatment-naïve patients with rheumatoid arthritis (RA). The hope is to identify predictive biomarkers for treatment response.
12. June 2024
Early RA: Disease Trajectories and Pain
New work to uncover disease evolution
—
People with rheumatoid arthritis (RA) tend to have different trajectories – both in how the disease evolves, and how disease states may improve over time. The frequency of pain patterns at diagnosis and over time – and their relationship with inflammation – also represents a gap in our knowledge. EULAR – The European Alliance of Associations for Rheumatology – recommend early identification and management for people with early arthritis.1 But understanding disease evolution and its influencing factors is important to identify opportunities to improve management and patient outcomes.
12. June 2024
Testing the Thresholds
Is the ASDAS appropriate for everyday clinical practice?
—
In patients with axial spondyloarthritis (axSpA) and persistent disease activity recommended to adapt treatment; treatment intensification should be considered for patients with persistently high disease activity. EULAR – The European Alliance of Associations for Rheumatology – in collaboration with the Assessment of SpondyloArthritis international Society (ASAS) state that high disease activity should be based on a composite score, the Ankylosing Spondylitis Disease Activity Score (ASDAS) with a cutoff ≥2.1.
12. June 2024
VEXAS: Towards Molecular and Phenotypic Characterisation
New work unveiled at EULAR 2024
—
VEXAS syndrome is a rare, adult-onset, life-threatening autoinflammatory disease caused by a genetic mutation. The pathophysiology is still unknown, but new work presented at the 2024 congress of EULAR – The European Alliance of Associations for Rheumatology – aims to provide a molecular and phenotypic characterisation of haematopoiesis in VEXAS patients, and to develop cellular and humanised mouse models by gene editing.
12. June 2024
Location, Location, Location – Does It Matter in Psoriatic Arthritis?
Exploring whether different joints have different treatment outcomes
—
There are many treatment options for psoriatic arthritis (PsA), and EULAR – The European Alliance of Associations for Rheumatology – recommend a practical and progressive approach to management based on specific manifestations and disease activity.1 But assessment of treatment outcomes primarily focuses on improvement in the number of affected joints, disregarding their specific locations.
12. June 2024
Can We Withdraw Treatment in Post-menopausal Osteoporosis?
European data released at EULAR 2024 echo findings from the US
—
Bisphosphonates are the recommended first-line treatment in post-menopausal osteoporosis, with denosumab recommended second-line.1 Based on the length of clinical trials for bisphosphonates, these drugs are usually prescribed for 3–5 years, or longer in patients who remain at high risk,2 and recent recommendations suggest long-term discontinuation after this period.2,3 However, data from the US suggest long-term discontinuation of bisphosphonates is associated with increased fracture risk.4 Until now, similar data from Europe have been lacking. New data on this topic are being shared at the 2024 congress of EULAR – The European Alliance of Associations for Rheumatology.
12. June 2024
Stopping the March
Can effective treatment of psoriasis prevent progression to PsA?
—
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis which appears in around one-third of people with psoriasis.1,2 EULAR – The European Alliance of Associations for Rheumatology – is committed to reducing the impact of rheumatic and musculoskeletal diseases on both the individual and society. At the 2024 EULAR congress, new Big Data suggest it could be possible to prevent the evolution from skin psoriasis to PsA.
07. June 2024
New: Classification Criteria for Hand OA
Distinguishing phenotypes for clinical trials
—
At present, classifying hand osteoarthritis (OA) is based on clinical
findings, and available tools are not able to distinguish between certain
phenotypes. With new disease-modifying treatments in development, trials will
require reliable classification criteria to ensure accurate comparisons between
groups. To support this, EULAR – The European Alliance of Associations for
Rheumatology – has developed new classification criteria for hand OA.
News of March 2024
25. March 2024
Latest Update for Psoriatic Arthritis
2023 update for key PsA recommendations
—
The options for psoriatic arthritis have grown markedly in recent years. To incorporate new agents and classes, EULAR - The European Alliance of Associations for Rheumatology - has once again updated its recommendations on the pharmacological management of psoriatic arthritis.
22. March 2024
Press Registration is Open for the EULAR 2024 Congress
A pivotal event in Rheumatology Research and Innovation
—
The European Alliance of Associations for Rheumatology, EULAR, is excited to announce that press registration is open for the EULAR 2024 Congress, taking place 12-15 June in Vienna, Austria.
News of February 2024
09. February 2024
New: Recommendations for Imaging in Crystal-Induced Arthropathies
Evidence-based recommendations for management of crystal-induced arthropathies
—
The first recommendations that encompass all major forms of crystal-induced arthropathies (CiA) and guide the use of common imaging modalities for this group of diseases in clinical practice have been published by EULAR – The European Alliance of Associations for Rheumatology.
02. February 2024
New: Points to Consider in Hyperinflammation
Streamlining consistency of care
—
EULAR – The European Alliance of Associations for Rheumatology – has worked in partnership with the American College of Rheumatology (ACR) to develop a set of new points-to-consider for two life-threatening syndromes that can develop in people with inflammatory diseases.
01. February 2024
New: CPPD Classification Criteria
First-ever validated criteria in this common yet neglected disease.
—
Calcium pyrophosphate deposition (CPPD) disease is a common, symptomatic arthritis, but until now there have been there are no validated classification criteria. This has hampered research in this common disease that becomes more frequent with increasing age. To address this, EULAR – The European Alliance of Associations for Rheumatology – has worked with the American College of Rheumatology (ACR) to develop the first-ever classification criteria.
News of January 2024
22. January 2024
Updated: Hip and Knee Osteoarthritis
Non-drug recommendations for people with hip or knee OA
—
Osteoarthritis (OA) is the most common joint disease worldwide, but it still remains without cure. EULAR – The European Alliance of Associations for Rheumatology – has updated its recommendations on the core management of hip and knee OA with non-pharmacological strategies.
News of December 2023
07. December 2023
New: Fatigue in Inflammatory RMD
New recommendations for management
—
EULAR – The European
Alliance of Associations for Rheumatology – has produced new recommendations focused on managing the key symptom of
fatigue. This common symptom is often overlooked, but it carries a significant
burden, and needs to be addressed.
06. December 2023
Updated: SLE Management
2023 recommendations for SLE
—
Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease that can affect all organs or tissues in the body. EULAR – The European Alliance of Associations for Rheumatology – has updated its recommendations for the management of this rheumatic disease, with guidance reflecting new understandings and new treatment options.
News of October 2023
30. October 2023
Updated: Antiphospholipid syndrome
Robust
classification criteria for clinical
research
—
EULAR - The European Alliance of Associations for Rheumatology - in collaboration with the American College of Rheumatology (ACR) has published updated classification criteria for antiphospholipid syndrome (APS).
News of August 2023
23. August 2023
Updated: Imaging Recommendations
Revised recommendations published in ARD
—
EULAR – The European
Alliance of Associations for Rheumatology – has reviewed its recommendations on the use of
imaging techniques such as ultrasound and magnetic resonance imaging (MRI) to
confirm diagnosis and support monitoring and outcome prediction in people with large vessel vasculitis (LVV).
07. August 2023
Non-Pharmacological Management for SLE and SSC
New recommendations published in ARD
—
For the first time, EULAR – The European Alliance of Associations for Rheumatology – has developed recommendations to provide guidance for non-pharmacological management of people living with Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc). These supportive options aim to help improve quality of life and self-care in people living with these rheumatic diseases.
News of July 2023
17. July 2023
New: Characterising the Transition from Skin to Joint in Psoriatic Disease
EULAR ‘points to consider’ published
in the Annals of the Rheumatic Diseases
—
Psoriatic arthritis (PsA) affects up to one-third of people with psoriasis. New evidence is emerging that supports the idea of a preclinical phase of the disease, with joint pain and imaging abnormalities preceding the diagnosis. EULAR – The European Alliance of Associations for Rheumatology – has developed a new set of points-to-consider to help characterize the transition from psoriasis to PsA.
News of June 2023
29. June 2023
Incoming EULAR Executive Director, Dr Stephan Maier
2023 EULAR welcomes New Executive Director
—
EULAR – The European Alliance of Associations for Rheumatology – is delighted to welcome Dr Stephan Maier, Switzerland, as the new Executive Director of the organisation, succeeding Dr Julia Rautenstrauch, Germany. Dr Maier will focus on leading the EULAR Team and driving the new EULAR Strategy to its vision, mission, and values.
05. June 2023
Daniel Aletaha New EULAR President
EULAR is excited to announce a change in its presidency, as Prof Annamaria Iagnocco, Italy, will be stepping down as President and handing over the role to Prof Daniel Aletaha, Austria.
—
EULAR welcomes Prof Daniel Aletaha, Vienna, Austria, as the new President of the organisation, succeeding Prof Annamaria Iagnocco, Turin, Italy. Prof Aletaha will lead EULAR in its mission to improve the lives of people with rheumatic and musculoskeletal diseases (RMDs), build on EULAR's successes, and drive EULAR forward. He is committed to continuing the work of his predecessor and taking the organisation to even greater heights.
02. June 2023
EULAR 2023: Understanding Opioids in Fibromyalgia
New work identifies factors associated with long-term use
—
EULAR – the European Alliance of Associations for Rheumatology – has recommendations for treatment of fibromyalgia. These advise that initial management should involve patient education and focus on nonpharmacological therapies. But with limited therapeutic options, opioids are frequently used in clinical practice. A team from the UK looked at how this translates into long-term use.
02. June 2023
EULAR 2023: New Insights into SLE-associated PAH
A 10-year multi-center cohort study
—
Pulmonary arterial hypertension (PAH) is a severe manifestation of systemic sclerosis (SSc) and systemic lupus erythematosus (SLE).1 Previous studies have described improved survival in SSc-associated PAH,2,3 but it is unclear whether the same pattern is seen in SLE-associated PAH.
02. June 2023
EULAR 2023: New Eustar Analysis
Targeted immunosuppression impacts prognosis in SSc-associated pulmonary hypertension
—
In this large EUSTAR cohort, immunosuppressive targeted therapies were associated with a significantly reduced risk of mortality and pre-capillary pulmonary hypertension worsening over time. This is the first large study to support a potential effect of targeted therapies in this group when adjusted for confounders. The abstract has been released at the 2023 annual congress of EULAR – the European Alliance of Associations for Rheumatology.
02. June 2023
EULAR 2023: Harnessing Patient Power
Patient organizations drive change in rheumatology
—
EULAR – the European Alliance of
Associations for Rheumatology – includes PARE, a network of national
organisations of People with Arthritis/Rheumatism across Europe. This body is
united in its mission to ensure the voice of people with rheumatic and
musculoskeletal diseases (RMDs) is heard. IPARE is a project group embedded in
the EULAR PARE sub-committee on community relations.
01. June 2023
EULAR 2023: EULAR Launches First European Patient-filled Survey The Impact of Rheumatic and Musculoskeletal Diseases on Individual’s Lives
First-of-its-kind online questionnaire allows collecting first-hand, longitudinal information about the impact of rheumatic and musculoskeletal diseases (RMDs) on the lives of patients across Europe
—
The
European Alliance of Associations for Rheumatology (EULAR) has announced the
launch of the EULAR Impact of RMDs Survey, an online questionnaire targeted
directly at RMD patients. The data collected through this survey will be an
important resource for researchers, healthcare professionals, and patients
alike, providing a comprehensive database of patient-reported outcomes on their
healthcare situation, and how the illness affects their social and occupational
lives.
01. June 2023
EULAR 2023: Managing Anxiety and Depression in Arthritis
Cross sectional nationwide study in Danish patients
—
In
2021, EULAR – the European Alliance of Associations for Rheumatology – published
recommendations for the implementation of self-management strategies in people
with inflammatory arthritis.1 These focused on empowering patients
to become active team partners and take a more proactive role.1 Now,
new data examine the link between self-management and mental health in this
patient group.
01. June 2023
EULAR 2023: Long-term Risks of Targeted Therapies
New data on cancer and cardiovascular risks
—
Janus kinase inhibitors (JAKi) and biologics are the cornerstone of modern treatment for rheumatoid arthritis (RA). But there have been concerns over long-term side effects. New data from a national healthcare database offer reassuring findings for overall cancers and cardiovascular disease (CVD).
01. June 2023
EULAR 2023: EULAR Launches Individual Membership in January 2023
New EULAR Individual Membership - Blue Membership Type
—
Starting from January 2023, EULAR has introduced its first Individual Membership type called Blue Membership. It is available to individuals who have paid the EULAR membership fee, regardless of their domicile.
01. June 2023
EULAR 2023: Rheumatic and Musculoskeletal Diseases (RMDs) often Accelerate Lethal Comorbidities
EULAR calls for a dedicated European strategy to combat RMDs.
—
Due to the belief that RMDs have a low mortality rate, they are often ignored in healthcare policy. However, patients can develop lethal comorbidities, such as cancer or cardiovascular disease, and the links between inflammatory RMDs and these comorbidities are becoming increasingly known in the medical field with the discovery of new medications and mechanisms of disease. Because of this, EULAR calls upon the European Union (EU) to create a dedicated RMD strategy to treat RMDs, reduce the risk of their comorbidities, and repurpose RMD drugs to treat other diseases.
01. June 2023
EULAR 2023: EULAR Launches ‘Rheumafacts’, A Unique and Pan-european Data Repository of Rheumatic and Musculoskeletal Disease Indicators
'RheumaFacts' draws a map of the socio-economic and healthcare realities in the field of rheumatology across Europe.
—
The European Alliance of Associations for Rheumatology (EULAR) is proud to announce the launch of RheumaFacts, an innovative and unique resource of facts and figures related to rheumatic and musculoskeletal diseases (RMDs) across Europe. Strategically developed to support EULAR’s mission of reducing the impact of RMDs on individuals and society, RheumaFacts will serve as a powerful tool to provide healthcare professionals, researchers, policymakers, and patients with data-driven insights on the status of rheumatologic care across EULAR’s member countries.
01. June 2023
EULAR 2023: The European Alliance of Associations for Rheumatology, EULAR, Announces its Strategy for 2024 – 2028
Extending EULAR’s leadership in rheumatic and musculoskeletal diseases and building a sound fundament for delivering expertise to the world
—
EULAR has generated considerable momentum in the sphere of rheumatic and musculoskeletal diseases (RMDs) through its various strategic activities over the past years. EULAR carries this momentum forward into the future through its new strategy. Driven by its vision to imagine a world in which all RMDs are recognised, diagnosed, and ultimately prevented or cured, EULAR will provide clear leadership in the relevant topics for the years to come.
01. June 2023
EULAR 2023: School Toolkits
Supporting children and young people with JIA
—
Juvenile idiopathic arthritis (JIA) is a group of autoimmune disorders characterized by chronic joint inflammation, and which starts in children under the age of 16. The disease has a considerable physical and psychological impact. EULAR – the European Alliance of Associations for Rheumatology – ran a session on JIA at the 2023 annual congress, which included an abstract on how to support JIA patients in education.
01. June 2023
EULAR 2023: Healthy Lifestyle and Mortality in Osteoarthritis
A prospective cohort study of the UK Biobank
—
Healthy lifestyles are thought to reduce mortality in the general population, but it is not known whether the same is true in osteoarthritis. Fan and colleagues present new data on the topic at the 2023 annual congress of EULAR – the European Alliance of Associations for Rheumatology.
News of May 2023
31. May 2023
EULAR 2023: FMF: Factors Associated with Delayed Diagnosis
Data from the JIR shine a light on this important autoinflammatory disease
—
Familial Mediterranean Fever (FMF) is the most common autoinflammatory disease worldwide. It affects mainly people of Mediterranean origin and is characterized by short, recurrent attacks of fever, and abdominal or thoracic pain lasting less than 3 days. Several studies report that diagnosis may be missed or delayed even in countries with a high FMF prevalence – but the real causes for the diagnostic delay are not completely known.
31. May 2023
EULAR 2023: COVID and RA
New data presented at the 2023 congress
—
The pandemic caused by SARS-CoV-2 (COVID-19) has had long-term effects, both on our economies and our heath. EULAR – the European Alliance of Associations for Rheumatology – was involved in registry efforts during the pandemic, and continues to advocate for patients with rheumatic and musculoskeletal diseases (RMDs) who remain affected by COVID.
31. May 2023
EULAR 2023: A Closer Look into Axial Spondyloarthritis
New data expand disease understanding
—
EULAR – The European Alliance of Associations for Rheumatology – welcomes delegates to its annual congress, taking place in Milan, Italy. Experts from around the world will showcase new ideas in scientific sessions and abstract presentations. This includes two from SPACE – the longitudinal SPondyloArthritis Caught Early cohort – and one from an online survey into regional differences in clinical phenotypes.
31. May 2023
EULAR 2023: Autoimmune Diseases Affect One in Ten
New research shared at the annual congress
—
So far there is a lack of reliable estimates of incidence, prevalence, and trends over time for autoimmune diseases. New research presented in Milan aims to change that, with data from a population-based study in over 22 million people.
31. May 2023
EULAR 2023: Exploring the Role of AI in Early RA
Can a computer replace human interpretation?
—
EULAR – the European Alliance of Associations for Rheumatology – begins its 2023 annual congress on 31st May in Milan, Italy. Among the data being presented, researchers from the Netherlands ask whether artificial intelligence interpretation of MRI images can provide more accurate predictions than visual scoring in early rheumatoid arthritis (RA).
31. May 2023
EULAR 2023: Cardiovascular Considerations in RA
New data at the 2023 congress
—
Patients with rheumatoid arthritis (RA) are at higher risk for cardiovascular disease than the general population. Systemic inflammation mediates some of this increased risk, therefore it seems logical that treatment with disease-modifying antirheumatic drugs (DMARDs) may be beneficial. A number of abstracts presented at the 2023 annual congress of EULAR – the European Alliance of Associations for Rheumatology – looked at cardiovascular data in RA.
31. May 2023
EULAR 2023: CV Risk in Psoriatic Arthritis
Building the link between inflammation and disease
—
Patients with psoriatic arthritis
(PsA) have an increased risk of cardiovascular disease, possibly due to a
chronic inflammatory state. New evidence shared at EULAR – the annual meeting
of the European Alliance of Associations for Rheumatology – supports this, showing that aortic vascular inflammation is
increased in patients with active PsA compared with controls.
31. May 2023
EULAR 2023: Physiotherapy in Your Pocket
Using Apps to support functional rehabilitation
—
Digital Apps may be useful to
support people with rheumatic and musculoskeletal diseases (RMDs) when they are
undergoing functional rehabilitation. New data shared at the annual congress of
EULAR – the European Alliance of Associations for Rheumatology – suggest that Apps which provide support for
exercise can significantly improve a range of outcomes, including physical
function, quality of life, and adherence
31. May 2023
EULAR 2023: Improving Access to Quality Patient Information
New points to consider for postgraduate programmes
—
May 2023 sees the return of the annual EULAR congress – the European Alliance of Associations for Rheumatology – representing patients, health professionals, and scientific societies in all the European nations. One of EULAR’s educational goals is to deploy innovative learning and facilitate broad access – an approach shared by the team involved in Lupus100.org, and outlined in their abstract at the meeting.
26. May 2023
NEW: Harmonising Rheumatology Training
New points to consider for postgraduate programmes
—
The structure and content of rheumatology training programmes varies quite widely across Europe, but with freedom of movement there is a need to standardise key aspects. EULAR – the European Alliance of Associations for Rheumatology – has worked in collaboration with the rheumatology section at the Union Européenne des Médecins Spécialistes (UEMS) to define standards for postgraduate programmes in rheumatology. The new competence-based document should help training providers to analyse their course content, and inspire positive change.
News of March 2023
23. Mar. 2023
NEW: Points to Consider on using Interferon Assays
EULAR ‘points to consider’ published
in the Annals of the Rheumatic Diseases
—
Type I interferons are involved in a wide range of immune functions. They have also been implicated in the development of autoimmune and anti-inflammatory process, which are the basis of many rheumatic and musculoskeletal diseases (RMD). Now, new points-to-consider from an expert consensus place them at the forefront of clinical research and practice.
20. Mar. 2023
Updated: AAV Treatment Recommendations
2022 update published in the Annals of the Rheumatic Diseases
—
EULAR – The European Alliance of Associations for Rheumatology – has updated its recommendations on the management of people with ANCA-associated vasculitis (AAV). Substantial changes have been made from the last version, taking into account new developments and clinical evidence in the field.
News of December 2022
12. Dec. 2022
Updated: GCA Classification Criteria
2022 update published in the Annals of the Rheumatic Diseases
—
EULAR – The European Alliance of Rheumatology Associations – together with the American College of Rheumatology (ACR), developed and validated new classification criteria for giant cell arteritis. The aim is to help ensure consistency in clinical trials and research, and to build on new advances in non-invasive and advanced imaging techniques.
9. Dec. 2022
Updated: Takayasu Classification
2022 update published in the Annals of the Rheumatic Diseases
—
EULAR – The European Alliance of Rheumatology Associations – together with the American College of Rheumatology (ACR) developed and validated new classification criteria for Takayasu arteritis. The aim is to ensure the consistency of inclusion rules for clinical trials and research in this disease, and to build on new advances in imaging.
News of November 2022
22. Nov. 2022
NEW: Screening and Treating Infections in AIIRD
Brand new guidance published in the Annals of the Rheumatic Diseases
—
EULAR – The European Alliance of Rheumatology Associations – has developed new recommendations for screening and prevention of chronic and opportunistic infections in people with autoimmune inflammatory rheumatic diseases (AIIRD). This is intended as a single point of reference to support routine practice and help identify how to check for and manage common infections.
11. Nov. 2022
Updated: RA Treatment Recommendations
2022 update published in the Annals of the Rheumatic Diseases
—
EULAR – The European Alliance of Rheumatology Associations – has updated its recommendations on disease-modifying treatment for people with rheumatoid arthritis (RA) to take into account developments and new evidence in the field. Three small changes and one major change have been implemented, the major change involving Janus kinase inhibitors.
9. Nov. 2022
Update: axSpA Recommendations
ASAS-EULAR updated recommendations published
—
EULAR – The European Alliance of Rheumatology Associations – has updated its recommendations for the management of axial spondyloarthritis (axSpA). In collaboration with ASAS – Assessment of SpondyloArthritis international Society – the new paper has been published in the Annals of the Rheumatic Diseases.
9. Nov. 2022
REVISED: ACR/EULAR REMISSION CRITERIA
Revisiting the criteria for remission in rheumatoid arthritis
—
In collaboration with the American College of Rheumatology (ACR), EULAR – The European Alliance of Rheumatology Associations – has developed a new set of criteria for defining remission in people with rheumatoid arthritis (RA).
1. Nov. 2022
NEW: REPORTING REQUIREMENTS IN RESEARCH
EULAR ‘points to consider’ published in the Annals of the Rheumatic Diseases
—
Synovial tissue makes up the lining of a joint, and is critical for its function. In order to help standardize data collection in this field, EULAR – the European Alliance of Associations for Rheumatology – propose a set of new points to consider for minimal reporting requirements in synovial tissue research.
1. Nov. 2022
NO IMPACT OF DIET ON RMD OUTCOMES
Systematic review and meta-analyses informing the new EULAR recommendations
—
In 2022, EULAR – the European Alliance of Rheumatology Associations – published new recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases (RMDs). Alongside these recommendations, the society has also made public the collated evidence and supporting analyses – including looking specifically at the impact of diet.
1. Nov. 2022
NEW: POINTS TO CONSIDER FOR DIAGNOSIS, TREATMENT AND MONITORING OF SYSTEMIC AUTOINFLAMMATORY DISEASES
EULAR ‘points to consider’ published in the Annals of the Rheumatic Diseases
—
Diagnosis and management of Systemic Autoinflammatory Diseases (SAIDs) can be challenging, and when left untreated people with severe SAIDs have poor prognosis. But there are life-changing treatments that can significantly improve outcomes. EULAR – The European Alliance of Rheumatology Associations – has developed a set of new points to consider in order to help improve care for people with these rare diseases.
News of October 2022
28. Oct. 2022
NEW: Standardised Ultrasound Courses
Agreeing the scope of paediatric musculoskeletal ultrasound courses in Europe
—
Despite the flourishing of paediatric musculoskeletal ultrasound courses in recent years, the content, conduct and format has never been internationally agreed. The current project is the first one dealing with the need of international standardised, high-level education in this imaging modality.
28. Oct. 2022
Update: Vaccination in Children with AIIRD
EULAR recommendations published in the Annals of the Rheumatic Diseases
—
EULAR – the European Alliance of Rheumatology Associations – has updated its recommendations on safe and effective vaccination and infection prevention in immunocompromised children with autoimmune/inflammatory rheumatic diseases (pedAIIRD).
28. Oct. 2022
NEW: Including Youth Perspectives
EULAR ‘points to consider’ published in the Annals of the Rheumatic Diseases
—
A range of patient-reported outcome measures (PROMs) with different features is available for people with inflammatory arthritis. However, the specific needs and priorities of younger patients have not been explored. EULAR – the European Alliance of Rheumatology Associations – set out to develop a new framework to include the perspectives of young patients with inflammatory arthritis.
28. Oct. 2022
Filling Data Gaps: Gender Equity in Academic Rheumatology
New empirical data generated by EULAR to inform a new task force
—
Gender equity can contribute to social progress and research quality. Yet, in many fields of academic medicine, women remain under-represented, especially in leadership roles. Based on survey data collected by EULAR, this study provides empirical evidence on the issue of gender equity in academic rheumatology.
20. Oct. 2022
NEW: Points to Consider to help People with an RMD stay in work
EULAR ‘points to consider’ published in the Annals of the Rheumatic Diseases
—
Rheumatic and musculoskeletal diseases (RMDs) are one of the leading causes of work disability, and account for up to 60% of prolonged sick leave and work disability in the European Union. EULAR – the European Alliance of Rheumatology Associations – has drafted a set of new points to consider to help people with RMDs engage in heathy and sustainable employment.
News of September 2022
15. Sep. 2022
EULAR Increases its Support to Improve Research Methods and Processes
The European Alliance of Associations for Rheumatology (EULAR) has launched a new funding opportunity to support European investigators interested in developing and evaluating innovative RMD research methods and tools. These are critically needed to find new solutions to the persistent unmet needs of people with rheumatic and musculoskeletal diseases
News of June 2022
4. Jun. 2022
EULAR 2022: 10 Years of Initiative: Analysis of the EMEUNET Mentoring Programme
Analysis of the EULAR mentoring programme
—
In 2012, the Emerging EULAR – the European Alliance of Associations for Rheumatology – Network (EMEUNET) started a mentoring programme in collaboration with the editorial board of top-leading journals in rheumatology, with the aim of improving peer reviewing skills of young researchers. Survey data presented at the 2022 EULAR Congress in Copenhagen show that after 5 editions over 10 years, the Mentoring Programme continues to be a valuable opportunity, with skill benefits for both mentees and mentors.
4. Jun. 2022
EULAR 2022: The Importance of Treatment Goals in PSA
New data show treatment goals are important, but perceptions may not be aligned
—
Results presented at the 2022 EULAR Congress show that early achievement of minimal disease activity (MDA) in psoriatic arthritis (PsA) is associated with long-term improvements in quality of life. Although this highlights the importance of setting and achieving goals early on in the disease, further multinational data released from the UPLIFT study suggest the majority of PsA patients are not aligned with their health care provider on the topic of treatment goals. This emphasises the need to improve communication around treatment goals in order to optimize patient outcomes.
3. Jun. 2022
EULAR 2022: Patient Involvement and Empowerment: Coping with Rheumatic Diseases
Projects benefit from inclusion of the patient voice
—
Having a rheumatic and musculoskeletal Disease (RMD) has an impact on daily activities, work, relationships, and quality of life. Patients may also feel a sense of invalidation. EULAR – The European Alliance of Associations for Rheumatology – has made efforts to raise awareness for the burden imposed by RMDs and promote the best quality of care, including recognition and psychosocial support. However, it is unclear how frequent and severe the problem remains nowadays. Several groups presenting findings at the 2022 EULAR Congress on patient empowerment and research aimed at helping people cope with living with an RMD.
3. Jun. 2022
EULAR 2022: Improving Treatment For Lupus Nephritis: New Data Released At EULAR
Findings support recommendations targeting early remission
—
Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE), and one of the most severe organ manifestations, affecting up to 40% of patients. It constitutes an important cause of morbidity and death among patients with SLE, and leads to end stage kidney disease (ESKD) in 17–33% after 10 years. The renal injury is the result of an immune-mediated process which involves leukocytes, immune complexes, complement, and cytokines. Data shared at the 2022 EULAR Congress include the development of chronic kidney disease (CKD), a post-hoc analysis of voclosporin data based on updated response criteria, and an integrated multilevel omics analysis that reveals pathways of potential interest for future drug targets.
3. Jun. 2022
EULAR 2022: Antimalarials And Electrocardiographic Alterations: New Data Bring Confidence
Two groups report findings at the EULAR Congress
—
Antimalarial drugs such as hydroxychloroquine are commonly used in the management of rheumatic diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). During the early stages of the COVID-19 pandemic, these agents were tested for patients with acute respiratory infection, with several studies reporting a risk of prolongation of corrected QT interval (QTc). Two groups have now released new findings on the relationship between antimalarials and electrocardiographic alterations in people with rheumatic diseases.
3. Jun. 2022
EULAR 2022: Osteoarthritis Represents Risk For Variety Of Comorbidities Across Different Organ Systems
But weight loss could represent and important management strategy
—
Osteoarthritis is one of the most common types of arthritis. It is commonly thought of as a degenerative disease, caused by wear and tear over time. This common and disabling disease places a significant burden on both patients and health care systems Three abstracts presented at the 2022 EULAR Congress in Copenhagen shed new light on risk of a wide range of comorbidities following osteoarthritis diagnosis, and the impact of body weight on structural defects and the need for knee replacement surgery. Results suggest prevention of overweight and obesity from young adulthood could have a major impact on the burden of knee osteoarthritis, and associated health care costs.
3. Jun. 2022
EULAR 2022: New Evidence Supporting COVID Severity Risk Factors In People With Diverse Rheumatic Diseases
New insights shared at the EULAR Congress
—
COVID-19 is the disease caused by SARS-CoV-2 infection. Some factors associated with severe COVID-19 outcomes have been identified in patients with inflammatory and autoimmune rheumatic and musculoskeletal diseases (RMDs), including older age, male sex, comorbidity burden, higher disease activity, and certain medications such as rituximab. New data released at the 2022 EULAR Congress shine a light on some specific factors for people with psoriasis, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), or idiopathic inflammatory myopathy (IIM).
3. Jun. 2022
EULAR 2022: Validation of EULAR Recommendations For Imaging In Giant Cell Arteritis
Ultrasound offers potential as a tool for diagnosis and monitoring in GCA
—
Giant cell arteritis (GCA) is a disease of the blood vessels, which causes inflammation in the artery lining. EULAR – the European Alliance of Associations for Rheumatology – has previously published recommendations for the use of imaging in large vessel vasculitis. Four new abstracts presented at the 2022 EULAR Congress in Copenhagen examined the use of ultrasound for the diagnosis and monitoring of GCA. Key findings establish that an imaging test supported by clinical pre-test probability is sufficient for the diagnosis of GCA; ultrasound is also confirmed as a potential tool for monitoring treatment response.
3. Jun. 2022
EULAR 2022: People With Rheumatic Diseases Have Deteriorated Sex Lives
Sexual dysfunction should be addressed in the management of RMDs
—
Chronic rheumatic and musculoskeletal diseases (RMDs) cause pain and disability, and can impair quality of life. RMDs also have an important impact on people’s sex lives. Two abstracts presented at the 2022 EULAR Congress in Copenhagen looked at how RMDs impact the sexual sphere, and how specialized physical therapy might be used to support some groups.
3. Jun. 2022
EULAR 2022: Air Pollution A Key Environmental Exposure Driving Inflammatory Arthritis Development
New evidence on pollutants and rheumatic disease shared at the 2022 EULAR Congress
—
Mounting evidence has shown that environmental exposures are linked to the development of inflammatory arthritis, with air pollution associated with disruption at a molecular level in the immune system. Pollutants can also have an impact on bone health. Data presented at the 2022 EULAR Congress in Copenhagen show that chronic exposures to air pollutants are associated with incremental increases in the risk of having an autoimmune disease. Meanwhile, a second research group demonstrate that cleaning activities are underestimated sources of silica exposure in women with RA compared to the general population, and may contribute to disease development.
3. Jun. 2022
New Data at EULAR 2022: Risk Factors For Severe COVID-19 Outcomes In A Large US Health Care System
More reliable analysis on larger populations is essential for current and future pandemics
—
COVID-19 is the disease caused by SARS-CoV-2 infection. Data from a large US health care system have been used to analyse COVID outcomes of patients with and without immune-mediated inflammatory diseases (IMIDs). Overall, patients with and without IMIDs had a similar rate of hospitalization, need for mechanical ventilation, and death. The strongest associations with COVID-19 severity included heart failure and age. Spondyloarthritis was weakly associated with favourable outcomes, whereas use of some rheumatic drugs was associated with increased hospitalization and mortality.
3. Jun. 2022
EULAR 2022: New Population-based Studies Show Increased Risk of Dementia and Depression in RA
New data presented at the 2022 EULAR Congress
—
Growing evidence from observational studies indicates that patients with rheumatoid arthritis (RA) have a higher risk of developing dementia. The occurrence of depression is also increased. New research shows depression is linked to increased mortality in this population. Clinically active RA was also associated with an elevated risk of dementia. Further studies are warranted to identify mechanisms of increased risk of dementia in RA patients.
2. Jun. 2022
EULAR 2022: New Data Align With EULAR Recommendations For Fibromyalgia Management
New data presented at the 2022 EULAR Congress
—
Patients with fibromyalgia suffer from high symptom burden and few available treatments. This condition is often found among patients newly referred to rheumatic outpatient clinics. It is well described that fibromyalgia patients have increased use of the secondary health care facilities. In line with recommendations from EULAR – the European Alliance of Associations for Rheumatology – timely and coordinated effort across medical specialties could reduce diagnostic delay, facilitate management, and reduce health care utilization in this population. Furthermore, mindfulness and acceptance-based interventions could deliver small improvements in pain, fatigue, and self-efficacy.
2. Jun. 2022
EULAR 2022: Immunogenicity of COVID Vaccines in People with Rheumatic Disease
New insights shared at the EULAR Congress
—
COVID-19 is the disease caused by SARS-CoV-2 infection. Initial studies on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases (IRD) reported diminished antibody responses, particularly for people treated with rituximab or abatacept. New data released at the 2022 EULAR Congress confirm that people on rituximab and abatacept should be prioritized for booster doses of COVID-19 vaccine.
2. Jun. 2022
EULAR 2022: Gaming for Adherence to Medication: Using E-Health in RA
New study data presented at the 2022 EULAR Congress
—
Effectiveness of treatment for rheumatoid arthritis (RA) is limited by inadequate adherence. Medication adherence can be influenced by implicit attitudes of personal medication needs and concerns about adverse events. The GAMER study targeted these attitudes using a serious puzzle game.
2. Jun. 2022
EULAR 2022: Mace Rates in the RABBIT Registry Lower Than Those Reported in Oral Surveillance
New real-world data presented at the EULAR Congress
—
In 2021, the EMA and FDA issued warnings about the cardiovascular safety of the Janus kinase inhibitor (JAKi) tofacitinib, and required changes in labelling. These actions were based on results of Oral Surveillance – a post-authorisation safety trial. Data released at the 2022 EULAR Congress now show the rate of major adverse cardiovascular events (MACE) in patients receiving JAKi in a real-world setting is lower than that reported for tofacitinib in Oral Surveillance.
2. Jun. 2022
EULAR 2022: COVID Breakthrough Infections: RMD Not Necessarily A Risk Group for Severe COVID-19
Prospective and registry data shared at EULAR 2022 support vaccine recommendations
—
COVID-19 is the disease caused by SARS-CoV-2 infection. Despite a wealth of vaccination data now available, concerns have been raised regarding risks of COVID-19 breakthrough infections in vaccinated patients with immune-mediated inflammatory rheumatic diseases (IRDs) treated with immunosuppressants. Two groups chose to share their findings at the EULAR Congress. These abstracts suggest that most patients with IRDs should not necessarily be seen as a risk group for severe COVID-19, and support the general recommendations to reduce the risk of severe infection by administering three doses of vaccine – especially in older patients, and those receiving immunomodulatory treatment.
2. Jun. 2022
EULAR 2022: Data Shared at EULAR Give Important Insights Into Treatment for RMD Patients Who Wish to Conceive
Some rheumatic treatments may affect fertility
—
Many rheumatic and musculoskeletal diseases (RMDs) affect people of child-bearing age, but there is often limited knowledge about the impact of these diseases and their treatment on fertility in both men and women. Two abstracts presented at the 2022 EULAR Congress in Copenhagen shine a light on some of the key factors affecting time to conception, and semen parameters. The results should be used to support discussions with patients who wish to conceive, and may help balance treatment needs.
2. Jun. 2022
EULAR 2022: Investigating Pregnancy Outcomes in Women with Rheumatic Disease
Several abstracts released at EULAR improve understanding of pregnancy in RMDs
—
An increased risk of adverse pregnancy and neonatal outcomes has been reported for pregnancies in women with several rheumatic and systemic autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). New data presented at the 2022 EULAR Congress in Copenhagen show that foetal morbidity and severe maternal morbidity occur at a higher rate in women with SLE compared to those without. An increased risk of adverse pregnancy outcomes was also reported for women with spondyloarthritis (SpA), and shown to be associated with steroid use in women with RA. Taken together, this range of findings will help inform physicians in their management of patients with RMDs during pregnancy and planning.
1. Jun. 2022
EULAR 2022: Data Support the Idea of a Treatment Window in the Pre-Arthritis Phase of Early RA
Suppressing inflammation in clinically suspect arthralgia may modify disease course
—
Rheumatoid arthritis (RA) is the most common autoimmune disease, and requires long-term treatment to suppress inflammation. Currently, methotrexate is initiated as first-line treatment when arthritis becomes clinically apparent with joint swelling. However, disease processes begin long before patients develop symptoms. New research published at the 2022 EULAR Congress in Copenhagen suggest that there is potential for a treatment window in the pre-arthritis early phase of RA, where limitations can be just as severe as at the onset of clinical arthritis. But it is also important to consider people’s socioeconomic factors, which may also have a bearing on progression to inflammatory arthritis.
1. Jun. 2022
EULAR 2022: Addressing Pain in Rheumatic Disease: Opioids and other Strategies
New data presented at the EULAR Congress in Copenhagen
—
Pain is an important consideration for people with rheumatic and musculoskeletal diseases (RMDs), which can restrict function and limit daily activities. Indeed, low back pain has been the leading cause of disability worldwide for the past 30 years. Opioid prescribing has contributed to a North American epidemic, with increasing trends in several European countries. RMDs are one of the most common indications for prescribed opioids, but there is being little evidence on their benefit. Several abstracts presented at the 2022 EULAR Congress aimed to address this knowledge gap, and develop other pain-relief strategies to reduce this chronic health burden.
1. Jun. 2022
EULAR 2022: New Insights Into Treatment Effectiveness in People with Axial Spondyloarthritis
Recognizing individual differences is important to be able to deliver personalized care
—
New evidence presented at the 2022 EULAR Congress reveals sex differences in physiology, disease presentation, and response to treatment in people with axial spondyloarthritis (axSpA), as well as the impact of non-steroidal anti-inflammatory drugs (NSAIDs) in people with radiographic disease
News of May 2022
17. May. 2022
NEW: EULAR Publication on Therapeutic Drug Monitoring in People with Rheumatic Disease
EULAR ‘points to consider’ published in the Annals of the Rheumatic Diseases
—
Therapeutic drug monitoring (TDM) refers to the principle of using blood concentrations of biopharmaceuticals to guide therapeutic decisions. EULAR – the European Alliance of Associations for Rheumatology – has developed a set of new ‘points to consider’ to support TDM in people with inflammatory rheumatic and musculoskeletal diseases (RMDs). This publication appears in the May 2022 issue of the Annals of the Rheumatic Diseases. The new points are evidence- and consensus-based statements addressing the clinical utility of TDM in RMDs. In general, proactive use of TDM is not recommended, but reactive TDM could be considered in certain clinical situations.
News of April 2022
29. Apr. 2022
Announcement: EULAR COVID-19 Registry to close
The EULAR/GRA COVID-19 Registry will be closing on the last day of the 2022 EULAR annual congress
—
Since early in the pandemic, EULAR – the European Alliance of Associations for Rheumatology – has been committed to collecting data to inform the understanding of COVID-19 in people with rheumatic and musculoskeletal diseases (RMDs), as well as outcomes following vaccination. In March 2020, EULAR partnered with the Global Rheumatology Alliance (GRA) to rapidly institute an online case registry. Over the past 2 years, this initiative has facilitated the collection of 12,908 cases in the EULAR registry, and over 22,000 in total across global provider registries. The information collected has informed clinical practice and the development of new recommendations. The next phase of the pandemic will benefit from detailed biologic data – such as SARS-CoV-2 variant characterisation, length of viral replication, immune response to vaccination, and detailed information on COVID-19 treatments to inform patient care. Future efforts should focus on the collection and analysis of this type of data; therefore, the EULAR/GRA COVID-19 Registry will close on 4th June 2022.
27. Apr. 2022
NEW: Lifestyle Recommendations
EULAR has released new recommendations to support lifestyle choices and help prevent the progression of rheumatic disease.
—
EULAR, the European Alliance of Associations for Rheumatology has written new evidence-based recommendations aimed at supporting healthy lifestyle choices and encouraging work participation in people with rheumatic and musculoskeletal diseases (RMDs). While some RMDs can be treated with drugs, this is not the case for all, and many people look for information about how they can modify their lifestyle or behaviours to help improve symptoms and prevent disease progression. These should be viewed as an integral part of management for people with RMDs, and should be regularly discussed in clinical practice.
News of March 2022
30. Mar. 2022
EULAR Announces Measures to Support Ukraine
EULAR has taken a series of decisions in view of Russia’s government attack on Ukraine
—
The European Alliance of Associations for Rheumatology, EULAR, strongly dissents Russia’s government attack on Ukraine, in violation of Ukraine’s sovereignty, territorial integrity, independence, and the welfare of its residents. As hospitals are being attacked and access to medical aid is interrupted, EULAR wants to respond to this humanitarian crisis and particularly support the Ukrainian people with rheumatic and musculoskeletal diseases (RMDs), who need urgent treatment and assistance.
15. Mar. 2022
Updated: COVID-19 Vaccination
Vaccination is the most important way to prevent COVID-19 infection, and to contain the ongoing pandemic. Several different types of COVID-19 vaccination are now available, and there has been much discussion about their use in people with rheumatic diseases. EULAR recommends that people with rheumatic diseases should be advised to receive any of the COVID-19 vaccines approved for use in their country. Based on the most current evidence, data, and expert opinions, the recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of COVID-19 has been updated.
7. Mar. 2022
NEW: Points to Consider in Research
Observational data are increasingly used to analyse the safety and effectiveness of new therapies in different subgroups. For effectiveness studies, authors typically report the proportion of patients reaching a defined clinical threshold after a set period of time. While comparing these outcomes is simple in randomised controlled trials, interpretation of comparative effectiveness is affected in observational studies by two key factors: confounding and selection bias.
News of February 2022
22. Feb. 2022
EULAR Recommendations for Cardiovascular Risk Management
People with inflammatory rheumatic diseases have an increased risk of cardiovascular disease (CVD), in comparison to the general population. Although recommendations exist for managing cardiovascular risks (CVR) in people with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, specific guidance was lacking for other rheumatic and musculoskeletal diseases (RMDs). Yet accumulating evidence shows increased cardiovascular morbidity and mortality in many other rheumatic conditions, including gout, systemic vasculitis and lupus.
7. Feb. 2022
Updated: Dealing with FAQ around COVID vaccination
EULAR has updated its guidance to help answer patients’ questions
—
COVID-19 vaccines have been shown to be safe and effective in people with rheumatic and musculoskeletal diseases (RMDs), as well as in people receiving drugs that influence the immune system. But people with inflammatory RMDs often have specific questions and concerns around vaccination, and the different types of vaccines available. New EULAR guidance is now available to help support health professionals in dealing with patient questions, and reassuring them about vaccination.
News of January 2022
7. Jan. 2022
New: COVAX results
Registry data reveal safety of COVID-19 vaccines in people with rheumatic and musculoskeletal diseases
—
In general, people with inflammatory or autoimmune rheumatic and musculoskeletal diseases (RMDs) have not been included in the clinical trial programs for COVID vaccines. This has led to questions about the safety and effectiveness of COVID vaccines in people with inflammatory RMDs. The COVAX registry aims to answer these questions and provide information about the safety of COVID vaccination in people with RMDs. This latest publication reveals data from over 5,000 people across a number of different RMDs and vaccine types. The findings should provide reassurance to health professionals and vaccine recipients, and promote confidence in the safety of COVID vaccination in people with inflammatory RMDs.
3. Jan. 2022
EULAR further steps up its Research Support
EULAR now provides European investigators with rapid funding support to overcome smaller resource gaps that may stall important research addressing the needs of people with rheumatic and musculoskeletal diseases.
—
Chronic and often painful rheumatic and musculoskeletal diseases (RMD) disable millions of people in the EU and worldwide [1]. Research is critical to better understand more than 200 of these conditions. Researchers often need to overcome roadblocks as they try to develop better prevention and treatments strategies. Because research support varies across Europe, the European Alliance of Associations for Rheumatology (EULAR) has launched a new rapid funding support programme to help researchers overcome smaller resource gaps that may stall necessary research on the needs of people with RMDs.
News of October 2021
22. Oct. 2021
Update: Repurposing rheumatology drugs for COVID-19
EULAR has updated its points to consider on the use of immunomodulatory drugs in the fight against severe COVID-19
—
COVID-19 is the disease caused by infection with the SARS-CoV-2 virus. Since it emerged at the end of 2019, the virus has caused a global pandemic. COVID-19 can be mild, or even without symptoms at all. But it can also cause severe disease, leading to respiratory problems, organ failure, and death. Research on the immune mechanisms involved in people with severe COVID-19 has shown that they have widespread inflammation. Early on in the pandemic, several immunomodulatory anti-inflammatory treatments commonly used in people with rheumatic and musculoskeletal diseases (RMDs) were proposed as possible options for people with severe COVID-19.
News of September 2021
17. Sep. 2021
New points to consider for achieving optimal results in a complex RA population
EULAR have developed new points to consider for managing difficult-to-treat RA
—
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. A significant proportion of people with RA still have symptoms despite receiving treatment according to the current management recommendations. These people can be considered to have ’difficult-to-treat RA’.
16. Sep. 2021
EU Shortage of arthritis drugs due to use as treatment for severe CV-19 cases
The European Alliance of Associations for Rheumatology, EULAR, wishes to highlight increasing shortages of vital anti-inflammatory drugs used in the treatment of arthritis, vasculitis and other inflammatory RMDs.
7. Sep. 2021
New EULAR Consensus on Prevention Trials in people at risk of developing RA
EULAR has released new points to consider for studies looking at preventing RA in people identified as at risk
—
In recent years, it has become clear that rheumatoid arthritis (RA) has a preclinical phase – a period before the disease has fully developed. This understanding has allowed the identification of people who are at risk of developing RA. There are a variety of genetic and environmental factors that make developing RA more likely. As autoantibodies and symptoms develop, these at-risk people eventually progress to clinical arthritis and classifiable RA. Despite growing interest in treatments to prevent RA, there is no guidance or consensus on how to conduct trials in at-risk populations.
6. Sep. 2021
EULAR Expands its Research Consultation Service
More extensive research expert services are now available to European investigators who seek to address the needs of people with rheumatic and musculoskeletal diseases, including advice about patient involvement strategies, pragmatic study designs, qualitative research methods, and EU grant preparation.
News of July 2021
2. Jul. 2021
EULAR Patient Research Partners participate in new EU research project HIPPOCRATES on Psoriatic Arthritis
Promoting early identification and improving outcomes for people with psoriatic arthritis
—
EULAR is one of 26 European research partners, including pharmaceutical companies, SME’s and patient organisations, to have joined forces to develop innovative personalised treatment options for people affected by psoriatic arthritis.
News of June 2021
18. Jun. 2021
Empowering people with Inflammatory Arthritis
EULAR has released new recommendations on self-management for people with inflammatory arthritis.
—
Inflammatory arthritis is a group of conditions characterised by pain and swelling in the joints. This is caused by underlying inflammation, driven by the body’s immune system attacking its own tissues – sometimes called autoimmune disease. Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. These each have their own definitions, and can affect different parts of the body, but they share the common feature of inflammation and joint symptoms.
10. Jun. 2021
EULAR Meritorious Service Awards 2021: Professor Maxime Dougados and Professor Josef Smolen named recipients
The European Alliance of Associations for Rheumatology, EULAR, named Maxime Dougados and Josef Smolen as the winners of the 2021 EULAR Meritorious Service Awards.
9. Jun. 2021
Incoming EULAR President Prof Annamaria Iagnocco Focuses on inclusion, cutting-edge education, and the new EULAR Strategy
EULAR welcomes Prof Annamaria Iagnocco, Turin, Italy, as the new president of the organisation, succeeding Prof Iain McInnes, Glasgow, UK. Prof Iagnocco will focus on inclusion and diversity and will set the milestones for the future EULAR strategy from 2023.
7. Jun. 2021
Improving uniformity and Quality of Care for people undergoing Intra-Articular Injection
EULAR releases new recommendations on the use of intra-articular therapies
—
Intra-articular therapies (IAT) are frequently used to treat joint conditions such as gout, rheumatoid arthritis, or osteoarthritis. The procedure involves inserting a needle into the space between the bones of the joint to deliver a drug. The types of injectables used in IAT techniques vary, from steroids to radiopharmaceuticals.
5. Jun. 2021
Understanding the impact of patient empowerment and remote management in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. In people with RA, low empowerment is associated with worse health. Interventions to improve empowerment may include helping people to master their pain, increase physical function, and improve physical activity. Remote technologies to support patient-reported self-assessment may help improve patient empowerment and disease management.
4. Jun. 2021
Decline in excess risk of dementia and heart failure in patients with Rheumatoid Arthritis
Data released at the 2021 EULAR congress show a substantial decline in the risk of both dementia and heart failure in people with rheumatoid arthritis (RA) onset in the 2000s as compared to 1980s – coinciding with the advent of novel biologic treatments for RA.
4. Jun. 2021
Impact of a national tender system on biologic and targeted drug costs in Norway
Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have caused a shift in the treatment of patients with inflammatory joint disorders, and remission is now attainable. But the high cost of these drugs has caused restrictions on their use and prescription, contributing to inequality of care worldwide. An annual tender system was introduced in 2008 in Norway to reduce the costs of these drugs.
4. Jun. 2021
Baseline medication use is associated with COVID-19 severity in people with Rheumatic Diseases
COVID-19 is the disease caused by SARS-CoV-2 infection. It has been suggested that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) may dampen the inflammatory response in COVID-19, perhaps leading to a less severe clinical course of the infection. However, the way some antirheumatic drugs work might impair the body’s natural immune defence against viruses. Two abstracts presented at EULAR 2021 show people taking rituximab or a class of drugs called janus kinase inhibitors (JAKi) have worse COVID-19 severity compared to people taking tumour necrosis factor inhibitors (TNFi). These data from two large registry initiatives highlight the urgent need for strategies to manage the risk in people taking antirheumatic drugs, such as identifying optimal timing for vaccination.
4. Jun. 2021
Pregnancy outcomes are affected by both maternal and paternal Inflammatory Disease
Data presented at the 2021 EULAR congress show women with rheumatoid arthritis (RA) are at increased risks of adverse pregnancy outcomes, especially pre-term birth and babies small for gestational age. For the first time, it has also been shown that the partners of men with inflammatory arthritis have a lower rate of live births, and are more likely to suffer a miscarriage. However, the link between disease activity, type and timing of antirheumatic treatment, and the risk of these outcomes remains unclear.
4. Jun. 2021
There is an unacceptable delay to diagnosis in Axial Spondyloarthritis
The current delay to diagnosis from symptom onset represents one of the greatest challenges in axial spondyloarthritis (axSpA) – a type of inflammatory arthritis affecting the back. Research shows an average delay of around 7 years – and up to 15 years in some cases – during which time the condition can progress and lead to irreversible damage. Data indicates that women wait longer than men for a diagnosis, and there has been very limited progress in reducing the time to diagnosis. This delay has a hugely detrimental impact on a person’s quality of life. Because the disease frequently has early onset, individuals are left untreated – or with incorrectly treated symptoms – at a formative period in their life course.
4. Jun. 2021
An increase in Giant Cell Arteritis cases associated with peaks in COVID-19 prevalence
Giant cell arteritis (GCA) is an inflammatory disease that affects the arteries, often causing headaches, jaw pain, and vision problems. The precise cause is not known, but infection is thought to play a role. Immediately following the first wave of the COVID-19 pandemic, the number of GCA diagnoses noticeably increased at the Royal National Hospital for Rheumatic Diseases in Bath, United Kingdom (UK). Furthermore, there was an increase in the proportion of patients with visual complications. The finding is important for understanding the underlying disease mechanisms in GCA, and supports the idea that viral infection could be involved. It also has implications for the provision of local services.
4. Jun. 2021
Genetic variant link with long-term incidence of Interstitial Lung Disease in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. Up to 10% of people with RA are affected by interstitial lung disease (ILD) during their lifetime, and ILD is one of the leading causes of death in patients with RA. Data presented at the 2021 EULAR congress report findings from a longitudinal study showing that people with MUC5B gene variant have a considerable lifetime risk of ILD, and that this gene variant contributes to increased morbidity. These findings have clinical implications for improving identification of people with RA who are at high risk for developing ILD.
3. Jun. 2021
COVID-19 morbidity and mortality in people with Rheumatic Diseases: New data and insights from Spain and Sweden
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is of particular concern for people with inflammatory diseases, and there are concerns that these people may be at higher risk and have poorer outcomes. However, at present the implications remain poorly understood. Population-based data from Spain show individuals with rheumatoid arthritis (RA) had an increased risk of COVID-19 diagnosis and hospitalization compared to the general population. Similarly, data from the ARTIS database in Sweden show risks of severe COVID-19 were increased among people with inflammatory joint diseases.
3. Jun. 2021
The true spread of SARS-COV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases
The true prevalence of COVID-19 is still unknown due to the high proportion of subclinical infection. Measuring seroprevalence may be crucial to improve knowledge about the impact of COVID-19 in rheumatic patients. Data shared at the 2021 EULAR congress highlight that the spread of SARS-CoV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases, but consistent with healthy population.
3. Jun. 2021
Inflammation of the eye after drug withdrawal in children with Arthritis
Uveitis is an inflammation of the eye and is a common extra-articular manifestation associated with juvenile idiopathic arthritis (JIA). It can cause vision-threatening complications, and if left uncontrolled may even lead to blindness. The majority of children develop uveitis within the first 2 years after arthritis symptom onset, but it can continue into adulthood. This is the first prospective study to analysed uveitis risk after drug withdrawal, and found that uveitis relapses are common. Rheumatologists and ophthalmologists should be aware and should plan for uveitis screening after drug withdrawal.
3. Jun. 2021
Elderly patients are not at increased risk of serious infections with new disease-modifying Antirheumatic drugs compared to conventional Synthetic treatments
Elderly people with rheumatoid arthritis (RA) are generally at increased risk of serious infections. At the same time, some anti-rheumatic treatments have been associated with a higher serious infection risk, but the extent to which older people are exposed to higher risks with some newer classes of therapy is an open question. Results of this study suggest that treatment with new classes of drugs is not associated with an increased risk of serious infection in elderly patients above 70 years of age.
3. Jun. 2021
Treatment with Tumour Necrosis Factor Inhibitors may slow disease progression in people with Spondyloarthritis
Sacroiliitis is an inflammation of the sacroiliac joints, situated where the lower spine and pelvis connect. Sacroiliitis is linked to the disease axial spondyloarthritis (axSpA) and visible on X-ray. Observational cohort studies have shown that there is low, but still detectable progression in radiographic sacroiliitis, which might also have an impact on the function in patients with axSpA. Recent data show that tumour necrosis factor inhibitors (TNFi) might slow spinal progression when started earlier and taken for longer. However, the question of whether they also have such an effect on radiographic progression in sacroiliac joints is still unclear.
2. Jun. 2021
First trial of Faecal Microbiota Transplantation for people with active Peripheral Psoriatic Arthritis shows no advantage
Results of the first trial of its kind presented at EULAR 2021
—
Targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel therapeutic option for people with extra-intestinal inflammatory diseases – although the link is yet to be established. In this first interventional randomised controlled trial of FMT in immune-mediated arthritis, transplantation was inferior to sham in treating active peripheral psoriatic arthritis.
2. Jun. 2021
Passive smoking and air pollution – links to Arthritis development and poor response to therapy
New data shared at the 2021 EULAR congress
—
There is increasing evidence that environmental air pollution is associated with people developing inflammatory arthritis. At the 2021 EULAR congress, a large population-based study of French women reports passive exposure to smoking during childhood or adulthood increases the risk of developing rheumatoid arthritis (RA). A second study in Italy found that air pollution also has an impact – with air pollution levels showing an association with failure of biologic therapy.
2. Jun. 2021
EULAR is working to accelerate Gender-Equitable career advancement in Academic Rheumatology
A framework and EULAR task force on gender equity in academic rheumatology
—
A growing number of professional societies in clinical and medical disciplines are investigating evidence, making recommendations, and taking action to advance gender equity.
News of April 2021
12. Apr. 2021
Points to consider for studies of work participation in people with Inflammatory Arthritis
A new publication from EULAR highlights the issues around designing, analysing, and reporting of studies using work participation as an outcome measurement.
—
Inflammatory arthritis is the name for a group of diseases that cause joint pain and swelling. This happens because the body’s immune system attacks its own tissues and causes inflammation. Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Inflammatory arthritis often affects people of working age, and can impact their employment. Work participation is often lower for people with inflammatory arthritis than the general population.
News of February 2021
17. Feb. 2021
EULAR: Supporting research at the Nexus of Science and the Clinic
EULAR launches new service to provide expert research advice for translational science investigators across Europe who want to develop solutions to the unmet needs of people with rheumatic and musculoskeletal diseases (RMDs).
12. Feb. 2021
Repurposing Rheumatology drugs for COVID-19
EULAR has released new points to consider on the use of immunomodulatory drugs in the fight against severe COVID-19
—
COVID-19 is the disease caused by infection with the SARS-CoV-2 virus. Since it emerged at the end of 2019, this virus has caused a global pandemic. COVID-19 can be mild, or even without symptoms at all. But it can also cause severe disease, leading to respiratory problems, organ failure, and death. Research on the immune mechanisms involved in people with severe COVID-19 has shown that they have widespread inflammation. Early on in the pandemic, several immunomodulatory anti-inflammatory treatments commonly used in people with rheumatic and musculoskeletal diseases (RMDs) were proposed as possible options for people with severe COVID-19.
5. Feb. 2021
Recognising young people’s perspectives in Inflammatory Arthritis
A new EULAR study shows that young people with arthritis need new ways to measure their function that take into account their age and lifestyle
—
Inflammatory arthritis is the name of a group of diseases that cause joint pain and swelling. This happens because the body’s immune system attacks its own tissues and causes inflammation. Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Although they may be thought of as older people’s conditions, these diseases can affect people at any age. Traditional patient-reported outcome measures (PROMs) record things like walking ability, which may not be relevant for young people early in their disease.
2. Feb. 2021
Characteristics associated with COVID-19-related death in people with Rheumatic and Musculoskeletal Diseases (RMDs)
New research examines the factors associated with COVID-19-related death in a large real-world dataset of people with rheumatic and musculoskeletal diseases
News of January 2021
1. Jan. 2021
EULAR announces 'European Alliance of Associations for Rheumatology’ as its new name
EULAR is pleased to announce the formal renaming of the organisation as ‘European Alliance of Associations for Rheumatology’, changing from ‘European League Against Rheumatism’, following the implementation of new EULAR Statutes, approved on 3 June 2020 by the General Assembly, entering into force on 1 January 2021.
News of December 2020
11. Dec. 2020
New: Core Data Set for Pregnancy Registries
EULAR established the first consensus-based core data set for prospective pregnancy registries in rheumatology. This will increase the knowledge about women with inflammatory rheumatic diseases (IRD) during pregnancy.
News of November 2020
19. Nov. 2020
EULAR: Improving research on rheumatic and musculoskeletal diseases across Europe together
EULAR launches new service to provide expert research advice for investigators across Europe who study ways to improve the lives of people with rheumatic and musculoskeletal diseases.
News of October 2020
12. Oct. 2020
EULAR: Workplace exclusion of people with arthritis compounded by COVID-19
The COVID pandemic has compounded the risks facing this vulnerable group and, with Europe facing the growing challenges of an ageing population and workforce, it is vital that the EU addresses the hidden costs of workplace exclusion for people suffering one of the over two hundred diseases under the RMD umbrella.
8. Oct. 2020
Unifying Terminology for Difficult-to-Treat Rheumatoid Arthritis
EULAR proposes a definition for difficult-to-treat RA in the hope of supporting clinical practice, trials, and research in the area.
—
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. A significant proportion of people with rheumatoid arthritis (RA) still have symptoms despite receiving treatment according to the current management recommendations. These people can be considered to have ’difficult-to-treat RA’. However, there is no uniform terminology or definitions to decide when this applies. The concept is referred to by many different terms, including severe, refractory, drug-resistant, or established RA. EULAR prefer the term ‘difficult-to-treat’ because it best capture the possible clinical scenarios. Being clear on terminology is important because people with difficult-to-treat RA may require a different approach.
News of September 2020
4. Sep. 2020
The EULAR School of Rheumatology wins Awards for excellence in learning
EULAR, a leader in innovative education in rheumatology, wins a coveted Brandon Hall Group awards for Excellence in Learning: Silver for Best Learning Team and bronze for Best Strategy for a Corporate Learning University.
News of August 2020
19. Aug. 2020
Osteoarthritis: Conservative Therapy Programme delays need for knee and hip joint replacement surgery
With implementation of conservative treatment methods like physiotherapy and individually tailored, adjusted exercises, quality of osteoarthritis care can improve and patients can delay the need for an artificial hip or knee joint.
18. Aug. 2020
EULAR: New best practice rheumatology training guidelines established by EULAR
Expert panel’s recommendations aim to further harmonise and improve rheumatology training and patient care in Europe.
12. Aug. 2020
Amputations of feet, toes and other body parts. The Combination of Diabetes and Gout significantly increases the risk
Compared to the average population, people suffering from both gout and diabetes have a 25 times higher risk of requiring an amputation of peripheral limbs such as feet, toes or lower legs.
News of July 2020
30. Jul. 2020
EULAR: Significant Increase For Impact Factor Of Annals Of The Rheumatic Diseases (ARD), The EULAR Journal, reflects rapidly improving quality of Rheumatology Research
The journal of the European League Against Rheumatism, ARD, has reached a new record, arriving at an impact factor of 16.102 this year, up from 14.299 last year.
27. Jul. 2020
Ankylosing Spondylitis (AS): Becoming a mother despite having a rheumatic disease? Study of Infants and Young Children Shows that Offspring Develop Normally
Women with ankylosing spondylitis (AS) can have children despite their rheumatic disease. But how do their children develop? A recent South Korean study has now come to the conclusion that the growth and development of infants and young children of mothers with AS are comparable to those of other mothers.
21. Jul. 2020
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19 associated Cytokine Storm related hospital mortality by 65%
New study demonstrates that a widely available immunosuppressant used for treatment of RMDs dramatically improves patient outcomes when compared to supportive care only.
7. Jul. 2020
Rheumatoid Arthritis Patients under Treatment with Methotrexate: Immunosuppressant Treatment does not confirm negative Effects on Lung Conditions in Patients
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).
News of June 2020
17. Jun. 2020
Early and intensive Treatment of rheumatoid Arthritis reduces Fatigue
Better quality of life for people with rheumatic and musculoskeletal diseases
9. Jun. 2020
European League Against Rheumatism (Eular) advocates the Deployment Of other Health Care Professionals – New Study confirms their Effectiveness
Insufficient health care for people with rheumatic diseases in Germany
9. Jun. 2020
New: Rheumatic Disease in the Context of COVID-19
The European League Against Rheumatism (EULAR) has published new provisional recommendations in response to the SARS-CoV-2 (COVID-19) pandemic
9. Jun. 2020
The European League Against Rheumatism, EULAR, launches Virtual Research Centre
Improving the lives of people with rheumatic and musculoskeletal diseases through research.
5. Jun. 2020
Thrombosis Risk particularly high for people suffering from rheumatic and musculoskeletal disease activity
Vigilance for thrombosis during the treatment of people with arthritis is particularly recommended. Moreover, maintaining therapies to keep disease activity under control is vital.
4. Jun. 2020
Rheumatic pain: increasingly more patients taking opioids; European league against rheumatism (EULAR) indicates the risk due to addiction
Fentanyl, tramadol or tilidine: New European figures show that even in Europe increasingly more people are taking opioids for pain connected with rheumatic and musculoskeletal diseases.
3. Jun. 2020
Study on COVID-19 in the Context of Rheumatic and Musculoskeletal Diseases Provides Reassurance to Patients on Immunosuppressive Medications
The results of the study will be presented in an online press conference in the context of the EULAR Congress on 3 June 2020.
News of May 2020
27. May. 2020
Update: EULAR Recommendations of the Pharmacological Treatment of Psoriatic Arthritis
The recommendations are designed to help physicians and health professionals choose the right drug for people with psoriatic arthritis (PsA). Due to the arrival of new drugs, the recommendations have been updated since their last update in 2015.
8. May. 2020
New: EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
These points to consider are designed to raise awareness and to assist rheumatologists to improve the diagnosis and the management of patients who develop side effects from checkpoint inhibitor drugs: rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of cancer patients receiving immune checkpoint inhibitors (ICI).
News of April 2020
29. Apr. 2020
New: Update of the joint EULAR/ERA-EDTA recommendations for the management of lupus nephritis
EULAR has published updated recommendations for the management of lupus nephritis. The update presents recent evidence on the use of certain drugs, disease monitoring and treatment targets.
27. Apr. 2020
EULAR: Hydroxychloroquine use in lupus patients ‘does not seem to prevent COVID-19’
ARD publishes first information regarding the impact of COVID-19 on patients with Systemic Lupus Erythematous already taking anti-malarial drug, Hydroxychloroquine.
17. Apr. 2020
EULAR encourages Europe to include expert view in shortages question
EULAR welcomes and supports the efforts to address shortages of medicines, including hydroxychloroquine, on the European market.
3. Apr. 2020
EULAR releases first reports on arthritis and COVID-19 in Italy
EULAR, has published two letters this week containing findings from COVID-19 cases concerning those suffering from rheumatic and musculoskeletal diseases in Italy.
3. Apr. 2020
EULAR President: Application of anti-malarials to tackle COVID-19 raises vital issues for rheumatic disease community in Europe
EULAR, welcomes global efforts aimed at increasing the information base around the potential for anti-malarial drugs in the treatment of COVID-19.
1. Apr. 2020
EULAR: Points to consider when using ‘big data’
EULAR, showcases its points to consider when using big data and computer-aided research methods in rheumatic and musculoskeletal diseases. The points are intended to provide a framework for rheumatologists, health professionals, patients and other stakeholders about how best to use big data and artificial intelligence to help answer important research questions.
1. Apr. 2020
EULAR releases recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
EULAR, has published recommendations for the management of patients with Sjögren’s syndrome with topical and systemic therapies. The therapeutic management of Sjögren’s syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal.
1. Apr. 2020
2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis
A EULAR task force of rheumatologists, health professionals and patients formulated three overarching principles and eight recommendations for the role of nurses in chronic inflammatory arthritis (CIA) care.
1. Apr. 2020
EULAR publishes 2018 update of evidence-based recommendations for diagnosis of gout
Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed and its management remains suboptimal, despite effective treatments.
News of March 2020
27. Mar. 2020
EULAR launches COVID-19 rheumatic and musculoskeletal diseases reporting database as part of Global Rheumatology Alliance
EULAR launches a European paediatric and adult database to monitor and report outcomes of COVID-19 occurring in patients with rheumatic and musculoskeletal diseases with the support of the Global Rheumatology Alliance.
25. Mar. 2020
2018 update of the EULAR recommendations for the management of large vessel vasculitis
A EULAR task force conducted a systematic literature review of recently published clinical trials and cohort analyses and sought opinion from 20 experts from 13 countries.
News of January 2020
28. Jan. 2020
EULAR Recommendations: RA management / Update 2019
EULAR has announced updated recommendations for the management of patients with rheumatoid arthritis (RA) in its newly published paper, ‘EULAR Recommendations for the management of rheumatoid arthritis with synthetic and disease-modifying antirheumatic drugs: 2019 update’.
News of November 2019
28. Nov. 2019
2019 update of EULAR Recommendations for vaccination in adult patients
25 November, 2019, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published updated recommendations for vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD).
News of October 2019
28. Oct. 2019
Press release: Core competences, HPRs in rheumatology
EULAR has published its first set of recommendations for the generic core competences of health professionals in rheumatology, with specific reference to nurses, physical therapists and occupational therapists.
News of July 2019
2. Jul. 2019
New EULAR President receives CBE and starts two-year term
Professor Iain McInnes has started his term in office as president of the European League Against Rheumatism
News of June 2019
7. Jun. 2019
EULAR Press Release: Patients with Sjögren's Syndrome in Europe
Patient's with Sjögren's Syndrome gather to take their destiny into their own hands.
News of May 2019
27. May. 2019
EULAR press release: Antiphospholipid syndrome in adults
The European League Against Rheumatism, EULAR, has published a set of recommendations for the management of antiphospholipid syndrome in adults
News of April 2019
4. Apr. 2019
New: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
4th April, 2019, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published an update to a set of recommendations for the management of systemic lupus erythematosus.
4. Apr. 2019
EULAR PARE Engagement Programme Press Release 2019
EULAR aims to engage with and support national organisations by providing a EULAR representative or speaker at their events.
News of October 2018
12. Oct. 2018
World Arthritis Day 2018: The press release
On World Arthritis Day ‘Don’t Delay, Connect Today’ Campaign educates on the importance of early diagnosis of rheumatic diseases.
7. Oct. 2018
EULAR Brussels Conference 2018
Get ready to join the EULAR Brussels Conference over livestream on Tuesday, 9 October!
News of July 2018
13. Jul. 2018
EULAR Recommendations on the effect of exercise and physical activity promotion in people with rheumatoid arthritis, spondyloarthritis and osteoarthritis
12th July, 2018, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published a set of recommendations for health professionals regarding physical activity in people with rheumatoid arthritis, spondyloarthritis and osteoarthritis. The recommendations report in detail on the meta-analysis that was performed to answer the question on the effectiveness of physical activity interventions.
News of June 2018
15. Jun. 2018
Press Release: Studies provide new insights into the role of sleep in chronic pain
Amsterdam, The Netherlands, 15 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into the role of sleep in chronic pain. The first study demonstrates a predictive role of sleep problems for chronic pain1 and the second provides insight into chronic pain and sleep in adolescents.
15. Jun. 2018
Press Release: Study suggests siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome
Amsterdam, The Netherlands, 15 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate an increased risk of acute coronary syndrome (ACS) in siblings of individuals with rheumatoid arthritis (RA), suggesting shared susceptibility between the two diseases.
15. Jun. 2018
Press Release: Obesity in women and current smoking in men predict lack of remission in early rheumatoid arthritis
Amsterdam, The Netherlands, 15 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) report that obesity in women and current smoking in men were the strongest predictors of not achieving remission in early rheumatoid arthritis (RA) within a year.
15. Jun. 2018
Press Release: Gout in the elderly linked to higher risk of dementia
Amsterdam, The Netherlands, 15 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest that gout is associated with a 17-20% higher risk of dementia in the elderly.
15. Jun. 2018
Press Release: Gum disease may be a key initiator of rheumatoid arthritis related autoimmunity
Amsterdam, The Netherlands, 15 June 2018: The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrates increased levels of gum disease, and disease-causing bacteria, in individuals at risk of rheumatoid arthritis (RA).
15. Jun. 2018
Press Release: Rates of depression and anxiety may correlate with disease activity in early rheumatioid arthritis
Amsterdam, The Netherlands, 15 June 2018: The results of a study to be presented at the Annual European Congress of Rheumatology (EULAR 2018) suggest that rates of anxiety and depression in patients with rheumatoid arthritis correlate with measures of disease activity over the first year following diagnosis.
15. Jun. 2018
Press Release: Obesity in childhood and adulthood shown to increase risk of knee and hip osteoarthritis
Amsterdam, The Netherlands, 15 June 2018: The results of a study to be presented at the Annual European Congress of Rheumatology (EULAR 2018) suggest childhood and adult obesity increase the risk of developing hip osteoarthritis (OA) and knee OA but not hand OA.
14. Jun. 2018
Press Release: Onset of depressive symptoms significantly associated with disease severity in patients with knee osteoarthritis
Amsterdam, The Netherlands, 14 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that among individuals with radiographic knee osteoarthritis (OA), decreased physical performance and greater structural disease severity are associated with a higher risk of experiencing depressive symptoms.
14. Jun. 2018
Press Release: Significant increase in self-harm attempts following ankylosing spondylitis diagnosis
Amsterdam, The Netherlands, 14 June 2018: The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate a significantly increased rate of self-harm attempts in inflammatory arthritis (IA), particularly following a diagnosis of Ankylosing Spondylitis (AS).
14. Jun. 2018
Press Release: Clinical advances in systemic lupus erythematosus
Amsterdam, The Netherlands, 14 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate exciting advances for individuals suffering from systemic lupus erythematosus (SLE).1,2 The first is a phase II clinical study of a promising oral treatment, baricitinib.1 The second demonstrates the effective use of the shingles vaccine* in SLE patients who are particularly prone to this infection.
14. Jun. 2018
Press Release: Rheumatoid arthritis in pregnancy associated with low birth weight and premature birth
Amsterdam, The Netherlands, 14 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that pregnancies in women with rheumatoid arthritis are associated with premature delivery and low birth weight.
14. Jun. 2018
Press Release: Youth-R-Coach: A peer-to-peer program for young people suffering with chronic disease
Amsterdam, The Netherlands, 14 June 2018: The details of a youth project presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate how, by empowering patients to become ‘experts-by-experience’, young people can give support to peers as well as provide insights into living with a chronic illness as a young person.
14. Jun. 2018
Press Release: Daily text message may improve adherence and treatment outcomes in patients with gout
Amsterdam, The Netherlands, 14 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate significant improvements in adherence and clinical outcomes in gout patients who received a daily text message to remind them to take allopurinol.
14. Jun. 2018
Press Release: Combining NSAIDs and TNF inhibitors may reduce radiographic progression in ankylosing spondylitis
Amsterdam, The Netherlands, 14 June 2018: The results of a cohort study presented at the Annual European Congress of Rheumatology (EULAR 2018) showed that, in patients with ankylosing spondylitis (AS) taking tumour necrosis factor (TNF) inhibitors, the addition of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with significantly less radiographic progression in a dose-related manner at four years.
14. Jun. 2018
Press Release: One year anniversary: EULAR Campaign
Amsterdam, The Netherlands, 14 June 2018: The European League Against Rheumatism (EULAR) today celebrated one year since the launch of its campaign, ‘Don’t Delay, Connect Today’, which was launched in June 2017 in Madrid, Spain. Now active in over twenty countries in Europe, and with more countries set to launch the campaign in the second half of the year, ‘Don’t Delay, Connect Today’ is gaining impact across all audiences, including at the political level in Europe.
13. Jun. 2018
Press Release: No difference in malignancy rates seen between tocilizumab and TNF inhibitors in patients with rheumatoid arthritis
Amsterdam, The Netherlands, 13 June 2018: The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi).
13. Jun. 2018
Press Release: Early, intensive treatment of rheumatoid arthritis provides long-term benefits and may normalise mortality rates
Amsterdam, The Netherlands, 13 June 2018: The results of a 23-year, follow-up study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest early, intensive treatment of rheumatoid arthritis has long-term benefits including the normalisation of mortality to levels consistent with the general population.
13. Jun. 2018
Press Release: Zoledronic acid shows no effect on knee pain or bone marrow lesions in knee osteoarthritis after two years
Amsterdam, The Netherlands, 13 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease.
13. Jun. 2018
Press Release: Canakinumab shown to reduce rates of gout in atherosclerosis by more than half
Amsterdam, The Netherlands, 13 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.
13. Jun. 2018
Press Release: New treatment lenebasum shows promise for diffuse cutaneous systemic sclerosis (dcSSc)
Amsterdam, The Netherlands, 13 June 2018: The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE).
13. Jun. 2018
Press Release: Launch of the EULAR Strategy 2018–2023
Amsterdam, The Netherlands, 13th June 2018: The European League Against Rheumatism (EULAR) has today presented its five-year strategy for the period 2018-2023 at the Annual European Congress of Rheumatology 2018. The strategy is the third strategic cycle in developing excellence in rheumatology in six areas of focus: Education, the annual congress, quality of care, research, advocacy and the internal organisation of EULAR.
13. Jun. 2018
Press Release: Gene signatures and biomarkers predict onset of rheumatoid arthritis in at-risk individuals
Amsterdam, The Netherlands, 13 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into molecular changes prior to the onset of arthritis which could inform future novel diagnostics and early therapeutic interventions.
13. Jun. 2018
Press Release: Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010
Amsterdam, The Netherlands, 13 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) investigate joint replacement procedures in rheumatoid arthritis (RA) patients.1,2 The first study demonstrates that joint replacement procedures have significantly reduced in RA patients in the past decade1 and the second investigates the impact of biologic therapies on this change using the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis (BSRBR/RA).
13. Jun. 2018
Press Release: NSAIDs shown to have casual role in cardiovascular risk of patients with osteoarthritis
Amsterdam, The Netherlands, 13 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest that over two thirds of the increased cardiovascular risk associated with osteoarthritis is linked to the use of non-steroidal anti-inflammatory drugs (NSAIDs).
13. Jun. 2018
EULAR School of Rheumatology: Launch of online 'learning landscape' and new educational offers
The EULAR School of Rheumatology membership for EUR 30 per annum provides access to the latest learning enviornment and content in rheumatology.
News of May 2018
14. May. 2018
New: EULAR Recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis
14th May, 2018, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published a set of recommendations, designed to help health professionals implement approaches to pain management in inflammatory arthritis and osteoarthritis patients. The aim is to reduce pain and the burden on the individual and society.
News of April 2018
17. Apr. 2018
Press release: EULAR Recommendations for the management of Behҫet’s syndrome
EULAR has published a set of recommendations, which look at the management of Behçet’s syndrome.
News of January 2018
29. Jan. 2018
Press Release: EULAR Recommendations for the use of imaging in large vessel vasculitis in clinical practise
A EULAR task force has formulated 12 recommendations which have been published in its journal, The Annals of Rheumatic Diseases, the leading scientific journal in rheumatology with an impact factor of 12.811.
News of December 2017
7. Dec. 2017
Press release: EULAR Recommendations
Actively optimising patient care in rheumatism: Contribution to and dissemination of key scientific findings in rheumatology are set out in the EULAR Recommendations – and translated into lay versions as well as local languages across Europe
News of October 2017
17. Oct. 2017
Press release: Investment beyond 2020
EULAR has called on the European Commission to maintain the EU’s position as global leader in health research. This includes continuing investment in research and developing a forward-looking agenda beyond the current research framework programme, Horizon 2020.
News of July 2017
6. Jul. 2017
EULAR School of Rheumatology Launch A 'Benefit to Humanity'
New ‘one roof structure’ for EULAR educational offerings, services and products gives international rheumatology community access to cutting-edge continued professional development.
5. Jul. 2017
New Editor for Annals of the Rheumatic Diseases
BMJ, a leading healthcare knowledge provider, is pleased to announce Josef Smolen as the new editor of Annals of the Rheumatic Diseases (ARD).
ARD is the top ranked journal in the field of rheumatology with an impact factor of 12.811.
News of June 2017
26. Jun. 2017
EULAR contributes 70 years to the field of RMDs
EULAR has released a press release to international media circles in celebration of its 70th anniversary.
Read the text and comments from EULAR President Prof. Gerd Burmester and President-elect Prof. Johannes Bijlsma.
22. Jun. 2017
EULAR Campaign: Don't Delay, Connect Today
The EULAR Campaign, Don't Delay, Connect Today, encompasses the three pillars of the association, scientific, health professionals and patient organisations. It was launched in Madrid, Spain, in mid-June.
Find information toolkits on the dedicated webpage, watch the video and get involved!
14. Jun. 2017
POSTMENOPAUSAL WOMEN AT RISK OF FRACTURES COULD BE IDENTIFIED THROUGH GENETIC PROFILING
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed for the first time that genetic markers, identified in previous research as being linked to the development of osteoporosis, are also associated with the risk of fragility fractures in postmenopausal women.
14. Jun. 2017
NEW STUDY SHOWS FOR FIRST TIME LINK BETWEEN PASSIVE SMOKING IN CHILDHOOD AND RHEUMATOID ARTHRITIS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference confirmed the link between active smoking and the risk of developing rheumatoid arthritis (RA). However, interestingly, it also suggested for the first time that in smokers, exposure to tobacco early in life through passive smoking in childhood significantly increased this risk.
14. Jun. 2017
NEW RELAPSE PREDICTION TOOL REDUCES COST OF RHEUMATOID ARTHRITIS TREATMENT
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 have shown that the combined use of two measurements to accurately predict the risk of relapse in patients with rheumatoid arthritis (RA) allows successful dose reduction (tapering) of their disease modifying anti-rheumatic drugs (DMARDs). This in turn increases the cost-effectiveness of each DMARD treatment.
14. Jun. 2017
NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).
14. Jun. 2017
GENES EXPLAIN HIGHER PREVALENCE OF CARDIOVASCULAR DISEASE IN CHRONIC IMMUNE MEDIATED INFLAMMATORY DISEASE PATIENTS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 represent an important step towards characterising the genetic basis of cardiovascular disease (CVD) risk in chronic immune-mediated inflammatory diseases (IMID).
14. Jun. 2017
EXCESS RISK OF CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS DECREASED SINCE START OF 21ST CENTURY
The results of a meta-analysis presented for the first time today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that the excess risk of cardiovascular events in rheumatoid arthritis (RA) patients relative to the general population has significantly decreased since the year 2000.
14. Jun. 2017
EDUCATION FOR PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES AND EMPLOYERS CAN IMPROVE ABILITY TO WORK
The results of an educational programme implemented by the Galician Rheumatology League (LRG), presented today at the Annual European Congress of Rheumatology (EULAR) 2017, showed that providing education and advice to people with rheumatic and musculoskeletal disease (RMD) and their employers can make a significant difference to the ability to work.
14. Jun. 2017
BIOSIMILAR CONCERNS OF RHEUMATOLOGY PATIENTS BEING ADDRESSED BY NATIONAL PROGRAMME
To address the fear and insecurity expressed by rheumatology patients on being switched from a biologic to a biosimilar treatment for their arthritis, the Danish Rheumatism Association has participated in a national programme designed to ensure patients received independent information about biosimilars, along with closer monitoring of prescriptions to provide reassurance about their safety. The results of this initiative were presented today at the Annual European Congress of Rheumatology (EULAR) 2017.
14. Jun. 2017
PERSISTENT PAIN SHOWS UP INEFFICIENCY OF CURRENT PSORIATIC ARTHRITIS (PsA) TREATMENT
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference have highlighted limitations in the current treatment of patients with Psoriatic Arthritis (PsA).
14. Jun. 2017
NURSES CRUCIAL IN IMPROVING UPTAKE OF POTENTIALLY LIFE-SAVING VACCINE IN VULNERABLE RHEUMATIC PATIENTS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that implementing a vaccination programme run by nursing staff dramatically improves pneumococcal vaccination coverage among vulnerable patients with chronic inflammatory rheumatic diseases.
14. Jun. 2017
NEW BLOOD TEST DETECTS STROKE AND HEART ATTACK RISK IN LUPUS PATIENTS WITH NO CARDIOVASCULAR SYMPTOMS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference have shown that a specific biomarker detected in the blood of lupus patients with no symptoms of cardiovascular disease (CVD), thought to be at low risk of CVD based on traditional risk factors, is associated with the presence of atherosclerosis.
14. Jun. 2017
LOW-DOSE CT SCANNING IMPROVES ASSESSMENT OF ANKYLOSING SPONDYLITIS PATIENTS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 showed that low dose computed tomography (LD-CT) is more sensitive than conventional radiographs (X-rays) in the monitoring of disease progression in patients with Ankylosing Spondylitis (AS).
14. Jun. 2017
COGNITIVE BEHAVIOUR THERAPY (CBT) SIGNIFICANTLY REDUCED DEPRESSION AND ANXIETY IN CHRONIC PAIN PATIENTS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 has shown that Acceptance and Commitment Therapy, a form of cognitive behavioural therapy (CBT) that focuses on psychological flexibility and behaviour change, provided a significant reduction in self-reported depression and anxiety among patients participating in a pain rehabilitation programme.
14. Jun. 2017
BIOLOGICAL DMARD GUIDELINES ASSOCIATED WITH A REDUCED NEED FOR KNEE AND HIP REPLACEMENTS IN RA PATIENTS
The results of a Danish study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that the incidence of total knee replacements (TKR) carried out on patients with rheumatoid arthritis (RA) started to decrease after the introduction of biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) to national treatment guidelines.
14. Jun. 2017
PREVIOUS BACTERIAL INFECTION INCREASES RISK OF NEWLY-DIAGNOSED SJÖGREN’S SYNDROME
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 have shown a link between newly-diagnosed Sjögren’s syndrome (SjS) and previous infection with nontuberculous mycobacteria (NTM).
14. Jun. 2017
NEW TOOLS HELP EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis (SSc).
14. Jun. 2017
NEW IMAGING TECHNIQUE MAY HELP IDENTIFY JOINT INFLAMMATION IN CHILDREN EARLIER AND WITH GREATER CONFIDENCE
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 have confirmed that Fluorescence Optical Imaging (FOI), a technique used to visualise inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis (JIA). FOI was also found to be more effective than US / PD at detecting inflammation in the absence of symptoms and signs.
14. Jun. 2017
NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference should reassure rheumatologists regarding the risk of cancer from the use of biological disease modifying anti-rheumatic drugs (bDMARDs), including anti-TNF treatment, in patients with rheumatoid arthritis (RA).
14. Jun. 2017
NEW CLASS OF DRUG SIGNIFICANTLY REDUCES SPINE FRACTURE RISK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.
14. Jun. 2017
EARLY THERAPEUTIC INTERVENTION FOR PRE-RHEUMATOID ARTHRITIS (PRE-RA) PATIENTS SIGNIFICANTLY REDUCES RISK OF RA
The results of a meta-analysis presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference has demonstrated that early therapeutic intervention in patients with so-called “pre-rheumatoid arthritis” (pre-RA) significantly reduces the risk of the occurrence of rheumatoid arthritis (RA) in these patients at 52 weeks or more.
14. Jun. 2017
CONTINUING ANTI-TNF TREATMENT WITH CZP FOR RA DURING PREGNANCY: NO OR NEGLIGIBLE PLACENTAL TRANSFER
The results of a pharmacokinetic study presented at the Annual European Congress of Rheumatology (EULAR) 2017 showed no or negligible placental transfer of the anti-TNF drug certolizumab pegol (CZP) from mothers to infants during pregnancy.
14. Jun. 2017
CONTINUING ANTI-TNF TREATMENT WITH CZP FOR RA DURING PREGNANCY: NO OR NEGLIGIBLE PLACENTAL TRANSFER
The results of a pharmacokinetic study presented at the Annual European Congress of Rheumatology (EULAR) 2017 showed no or negligible placental transfer of the anti-TNF drug certolizumab pegol (CZP) from mothers to infants during pregnancy.
14. Jun. 2017
BODY FAT AND WAIST SIZE LINKED TO INCREASED RISK OF DEVELOPING RHEUMATOID ARTHRITIS IN WOMEN
The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 showed that, in women, being overweight or obese, as defined by body mass index (BMI*), abdominal obesity and a higher body fat percentage was associated with a higher risk of developing rheumatoid arthritis (RA).
1. Jun. 2017
EULAR launches 'RheumaMap’ in EU Parliament in Brussels
In a meeting of the Interest Group on Rheumatic and Musculoskeletal Diseases (RMDs), the “Research Roadmap to transform the lives of people with Rheumatic and Musculoskeletal Diseases” was launched in the European Parliament.